Linda A.J. Hendricks , Katja C.J. Verbeek , Janneke H.M. Schuurs-Hoeijmakers , Mirjam M. de Jong , Thera P. Links , Hilde Brems , Mio Aerden , Joan Brunet , Roser Lleuger-Pujol , Robert Hüneburg , Stefan Aretz , Chrystelle Colas , Marie-Charlotte Villy , Emma R. Woodward , D. Gareth Evans , Daniëlle G.M. Bosch , Stephany H. Donze , Lenka Foretová , Ana Blatnik , Edward M. Leter , Janet R. Vos
{"title":"PTEN错构瘤肿瘤综合征(PHTS)发生第二原发癌的风险。","authors":"Linda A.J. Hendricks , Katja C.J. Verbeek , Janneke H.M. Schuurs-Hoeijmakers , Mirjam M. de Jong , Thera P. Links , Hilde Brems , Mio Aerden , Joan Brunet , Roser Lleuger-Pujol , Robert Hüneburg , Stefan Aretz , Chrystelle Colas , Marie-Charlotte Villy , Emma R. Woodward , D. Gareth Evans , Daniëlle G.M. Bosch , Stephany H. Donze , Lenka Foretová , Ana Blatnik , Edward M. Leter , Janet R. Vos","doi":"10.1016/j.gim.2025.101467","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Patients with PTEN Hamartoma Tumor Syndrome (PHTS) have high hereditary cancer risks for breast, endometrial, and thyroid cancer. Patients develop multiple primary cancers, but these risks remain uncertain. We aimed to provide the second primary cancer risk.</div></div><div><h3>Methods</h3><div>This European cohort study assessed second primary cancer risks with Kaplan-Meier analyses using data from medical files, registries and/or patient questionnaires.</div></div><div><h3>Results</h3><div>Overall, 279 adult PHTS patients with (a history of) cancer were included (80% female). Among females, 106 (54%) developed a PHTS-related second primary cancer after a PHTS-related first primary cancer, whereas 10 (29%) males developed a PHTS-related second primary cancer after a PHTS-related first primary cancer. The 5- and 10-year PHTS-related second primary cancer risks were 24.5% (95% CI = 18.1-32.5) and 45.7% (95% CI = 36.9-55.4) in females and 14.5% (95% CI = 5.7-34.1) and 19.8% (95% CI = 8.6-41.9) in males, respectively. Furthermore, 5- and 10-year risks for a second primary breast cancer after a first primary breast cancer were 23.3% (95% CI = 14.9-35.2) and 45.6% (95% CI = 33.0-60.2) in females, respectively.</div></div><div><h3>Conclusion</h3><div>This study demonstrated that PHTS patients have high second primary cancer risks, which is driven by breast cancer in females. Hence, identifying patients with PHTS before or at first primary cancer diagnosis is essential to enable potential early detection or prevention of a second primary cancer through surveillance or risk-reducing surgery.</div></div>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":"27 10","pages":"Article 101467"},"PeriodicalIF":6.2000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS)\",\"authors\":\"Linda A.J. Hendricks , Katja C.J. Verbeek , Janneke H.M. Schuurs-Hoeijmakers , Mirjam M. de Jong , Thera P. Links , Hilde Brems , Mio Aerden , Joan Brunet , Roser Lleuger-Pujol , Robert Hüneburg , Stefan Aretz , Chrystelle Colas , Marie-Charlotte Villy , Emma R. Woodward , D. Gareth Evans , Daniëlle G.M. Bosch , Stephany H. Donze , Lenka Foretová , Ana Blatnik , Edward M. Leter , Janet R. Vos\",\"doi\":\"10.1016/j.gim.2025.101467\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Patients with PTEN Hamartoma Tumor Syndrome (PHTS) have high hereditary cancer risks for breast, endometrial, and thyroid cancer. Patients develop multiple primary cancers, but these risks remain uncertain. We aimed to provide the second primary cancer risk.</div></div><div><h3>Methods</h3><div>This European cohort study assessed second primary cancer risks with Kaplan-Meier analyses using data from medical files, registries and/or patient questionnaires.</div></div><div><h3>Results</h3><div>Overall, 279 adult PHTS patients with (a history of) cancer were included (80% female). Among females, 106 (54%) developed a PHTS-related second primary cancer after a PHTS-related first primary cancer, whereas 10 (29%) males developed a PHTS-related second primary cancer after a PHTS-related first primary cancer. The 5- and 10-year PHTS-related second primary cancer risks were 24.5% (95% CI = 18.1-32.5) and 45.7% (95% CI = 36.9-55.4) in females and 14.5% (95% CI = 5.7-34.1) and 19.8% (95% CI = 8.6-41.9) in males, respectively. Furthermore, 5- and 10-year risks for a second primary breast cancer after a first primary breast cancer were 23.3% (95% CI = 14.9-35.2) and 45.6% (95% CI = 33.0-60.2) in females, respectively.</div></div><div><h3>Conclusion</h3><div>This study demonstrated that PHTS patients have high second primary cancer risks, which is driven by breast cancer in females. Hence, identifying patients with PHTS before or at first primary cancer diagnosis is essential to enable potential early detection or prevention of a second primary cancer through surveillance or risk-reducing surgery.</div></div>\",\"PeriodicalId\":12717,\"journal\":{\"name\":\"Genetics in Medicine\",\"volume\":\"27 10\",\"pages\":\"Article 101467\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2025-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genetics in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1098360025001145\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetics in Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1098360025001145","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS)
Purpose
Patients with PTEN Hamartoma Tumor Syndrome (PHTS) have high hereditary cancer risks for breast, endometrial, and thyroid cancer. Patients develop multiple primary cancers, but these risks remain uncertain. We aimed to provide the second primary cancer risk.
Methods
This European cohort study assessed second primary cancer risks with Kaplan-Meier analyses using data from medical files, registries and/or patient questionnaires.
Results
Overall, 279 adult PHTS patients with (a history of) cancer were included (80% female). Among females, 106 (54%) developed a PHTS-related second primary cancer after a PHTS-related first primary cancer, whereas 10 (29%) males developed a PHTS-related second primary cancer after a PHTS-related first primary cancer. The 5- and 10-year PHTS-related second primary cancer risks were 24.5% (95% CI = 18.1-32.5) and 45.7% (95% CI = 36.9-55.4) in females and 14.5% (95% CI = 5.7-34.1) and 19.8% (95% CI = 8.6-41.9) in males, respectively. Furthermore, 5- and 10-year risks for a second primary breast cancer after a first primary breast cancer were 23.3% (95% CI = 14.9-35.2) and 45.6% (95% CI = 33.0-60.2) in females, respectively.
Conclusion
This study demonstrated that PHTS patients have high second primary cancer risks, which is driven by breast cancer in females. Hence, identifying patients with PHTS before or at first primary cancer diagnosis is essential to enable potential early detection or prevention of a second primary cancer through surveillance or risk-reducing surgery.
期刊介绍:
Genetics in Medicine (GIM) is the official journal of the American College of Medical Genetics and Genomics. The journal''s mission is to enhance the knowledge, understanding, and practice of medical genetics and genomics through publications in clinical and laboratory genetics and genomics, including ethical, legal, and social issues as well as public health.
GIM encourages research that combats racism, includes diverse populations and is written by authors from diverse and underrepresented backgrounds.